Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.55 |
| ▸ | ILK | Q13418 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 9/20 | 0.52 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 6/20 | 0.49 |
| ▸ | KIF5B | P33176 | 4/20 | 0.49 |
| ▸ | JAK3 | P52333 | 3/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.48 |
| ▸ | GAK | O14976 | 2/20 | 0.48 |
| ▸ | STK10 | O94804 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.48 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.48 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13646413 | 0.91 | EGFR (0.63) | EGFRILKKDRKDM1AFLT1 | |
| SCHEMBL3875034 | 0.85 | EGFR (0.49) | EGFRILKKDRFLT1FGFR1 | |
| SCHEMBL3871041 | 0.84 | EGFR (0.59) | EGFRILKKDRKDM1AFLT1 | |
| SCHEMBL13646416 | 0.81 | EGFR (0.63) | EGFRILKKDRKDM1AFLT1 | |
| SCHEMBL13646428 | 0.81 | EGFR (0.70) | EGFRILKKDRKDM1AFLT1 | |
| SCHEMBL13646435 | 0.79 | FBP1 (0.71) | EGFRKDRAURKAERBB2PDGFRB | |
| SCHEMBL3875759 | 0.79 | EGFR (0.80) | EGFRILKKDRKDM1AFLT1 | |
| SCHEMBL13646432 | 0.79 | EGFR (0.75) | EGFRILKKDRKDM1AFLT1 | |
| SCHEMBL13646431 | 0.79 | FBP1 (0.70) | EGFRILKKDRKDM1AFLT1 | |
| Erlotinib SCHEMBL13087124 | 0.77 | EGFR (0.78) | EGFRILKKDRKDM1AFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | ABL1, FLT3, GRK5 | EGFR 19/4885ILK 2741/4885KDR 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.